BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302535% above fair value
$403.60−9.66 (-2.34%)
Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –
BeOne Medicines free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
BeOne Medicines's free cash flow for the twelve months ending Jun 30, 2026 was $1.33B, up 443.3% year over year. For fiscal 2025 it was $941.74M. The highest annual figure on record is $941.74M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $941.74M | – |
| FY2024 | Dec 31, 2024 | -$633.29M | – |
| FY2023 | Dec 31, 2023 | -$1.72B | – |
| FY2022 | Dec 31, 2022 | -$1.82B | – |
| FY2021 | Dec 31, 2021 | -$1.56B | – |
| FY2020 | Dec 31, 2020 | -$1.40B | – |
| FY2019 | Dec 31, 2019 | -$839.88M | – |
| FY2018 | Dec 31, 2018 | -$618.00M | – |
| FY2017 | Dec 31, 2017 | -$33.62M | – |
| FY2016 | Dec 31, 2016 | -$113.02M | – |
| FY2015 | Dec 31, 2015 | -$45.16M | – |
| FY2014 | Dec 31, 2014 | -$9.35M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $435.34M | +98.1% |
| Q1 FY2026 | Mar 31, 2026 | $160.55M | – |
| Q4 FY2025 | Dec 31, 2025 | $379.83M | – |
| Q3 FY2025 | Sep 30, 2025 | $354.47M | +547.9% |
| Q2 FY2025 | Jun 30, 2025 | $219.77M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.32M | – |
| Q3 FY2024 | Sep 30, 2024 | $54.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$205.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$465.15M | – |
| Q4 FY2023 | Dec 31, 2023 | -$378.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$236.03M | – |
| Q2 FY2023 | Jun 30, 2023 | -$415.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$689.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$439.55M | – |
| Q3 FY2022 | Sep 30, 2022 | -$670.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$430.25M | – |
| Q1 FY2022 | Mar 31, 2022 | -$281.69M | -440.6% |
| Q4 FY2021 | Dec 31, 2021 | -$622.82M | – |
| Q3 FY2021 | Sep 30, 2021 | -$562.76M | – |
| Q2 FY2021 | Jun 30, 2021 | -$458.80M | – |
| Q1 FY2021 | Mar 31, 2021 | $82.71M | – |
| Q4 FY2020 | Dec 31, 2020 | -$367.02M | – |
| Q3 FY2020 | Sep 30, 2020 | -$374.92M | – |
| Q2 FY2020 | Jun 30, 2020 | -$295.55M | – |
| Q1 FY2020 | Mar 31, 2020 | -$363.48M | – |
| Q4 FY2019 | Dec 31, 2019 | -$282.65M | – |
| Q3 FY2019 | Sep 30, 2019 | -$295.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$67.55M | – |
| Q1 FY2019 | Mar 31, 2019 | -$193.80M | – |
| Q4 FY2018 | Dec 31, 2018 | -$217.15M | -390.2% |
| Q3 FY2018 | Sep 30, 2018 | -$158.91M | – |
| Q2 FY2018 | Jun 30, 2018 | -$127.75M | – |
| Q1 FY2018 | Mar 31, 2018 | -$114.20M | – |
| Q4 FY2017 | Dec 31, 2017 | $74.82M | – |
| Q3 FY2017 | Sep 30, 2017 | -$11.96M | – |
| Q2 FY2017 | Jun 30, 2017 | -$55.70M | – |
| Q1 FY2017 | Mar 31, 2017 | -$40.78M | – |
| Q4 FY2016 | Dec 31, 2016 | -$34.20M | – |
| Q3 FY2016 | Sep 30, 2016 | -$30.96M | – |
See a number that looks wrong?